Interchangeability of biosimilars around the world

Home/Reports | Posted 02/06/2017 post-comment0 Post your comment

There is a lack of harmonization around the world when it comes to how different countries or regions approach interchangeability of biosimilars [1].

Harmonize V13F28

USA
In the US interchangeability is defined in law as part of the Biologics Price Competition and Innovation Act.

The US Food and Drug Administration may approve a product as interchangeable. Although individual states control the act of pharmacy-level substitution.

European Union
The European Commission has defined interchangeability in a consensus information document on biosimilars [4].

In the European Union, decisions on the interchangeability or substitution of biosimilars and originator biologicals are not made by the European Medicines Agency, but at the national level.

Canada
In Canada, where biosimilars were previously referred to as subsequent entry biologics, the medicines regulatory agency Health Canada has not defined interchangeability for biosimilars.

Health Canada does not designate biosimilars as interchangeable and does not support automatic substitution. Decisions on interchangeability are made at the province level.

Australia
Australia’s Pharmaceutical Benefits Advisory Committee can designate biosimilars as interchangeable, known as ‘a-flagging’. 

In Australia the payer body has the exclusive authority to determine substitution of biosimilars at the pharmacy level. The substitution of biosimilars is recommended as its default policy.

The lack of harmonization for the interchangeability of biosimilars across the world introduces confusion for stakeholders and developers.

Editor’s comment
This article for GaBI Online is a summary of the full article [1] published in GaBI Journal.

If you would like to receive a copy of the GaBI Journal article, please send us an email.

Related articles
Interchangeability of biosimilars in the US

The evolution of biosimilars in the US 

Efficacy, extrapolation and interchangeability of biosimilars

Reference
1. Derbyshire M. Interchangeability of biosimilars in the US and around the world. Generics and Biosimilars Initiative Journal (GaBI Journal). 2017;6(2):97-8. doi:10.5639/gabij.2017.0602.017

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
Brazilian market of biosimilars
Brazil flag V13C03
Home/Reports Posted 20/05/2022
China–EU market expansion for biosimilars
18794124_l
Home/Reports Posted 16/05/2022
Most viewed articles
About GaBI
Home/About GaBI Posted 06/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010